Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: A randomised controlled phase 3 trial

The Lancet

Volumn 380, Issue 9856, 2012, Pages 1829-1839

  Coles, Alasdair J ^a   Twyman, Cary L ^d   Arnold, Douglas L ^b   Cohen, Jeffrey A ^c   Confavreux, Christian ^e   Fox, Edward J ^f   Hartung, Hans Peter ^g   Havrdova, Eva ^h   Selmaj, Krzysztof W ⁱ   Weiner, Howard L ^j   Miller, Tamara ^k   Fisher, Elizabeth ^c   Sandbrink, Rupert ^g,l   Lake, Stephen L ^m   Margolin, David H ^m   Oyuela, Pedro ^m   Panzara, Michael A ^m   Compston, D Alastair S ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b MCGILL UNIVERSITY   (Canada)

^c LERNER RESEARCH INSTITUTE   (United States)

^d Université Claude Bernard Lyon 1 ^*

^e UNIVERSITÉ LYON 1   (France)

^f MS Clinic of Central Texas   (United States)

^g HEINRICH HEINE UNIVERSITY   (Germany)

^h CHARLES UNIVERSITY   (Czech Republic)

ⁱ MEDICAL UNIVERSITY OF LODZ   (Poland)

^j Brigham and Women's Hospital Center for Neurologic Diseases   (United States)

^k Bayer HealthCare   (United States)

^l BAYER PHARMA AG   (Germany)

^m GENZYME CORPORATION   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; ANTIHISTAMINIC AGENT; ANTIPYRETIC AGENT; AZATHIOPRINE; BETA1A INTERFERON; GLATIRAMER; IMMUNOGLOBULIN; INTERFERON BETA SERINE; METHYLPREDNISOLONE; NATALIZUMAB;

ADULT; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISABILITY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FEVER; HAZARD RATIO; HERPES SIMPLEX; HUMAN; IMMUNE THROMBOCYTOPENIA; INFECTION; INFUSION SITE REACTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE FREE SURVIVAL; RELAPSE; THYROID DISEASE; TREATMENT DURATION; TREATMENT RESPONSE; VOICE;

EID: 84869507357     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(12)61768-1     Document Type: Article

References (32)

1. Rudick RA, Lee JC, Simon J, Ransohoff RM, Fisher E. Defining interferon beta response status in multiple sclerosis patients. Ann Neurol 2004; 56: 548-55.
2. Prosperini L, Gallo V, Petsas N, Borriello G, Pozzilli C. 1-year MRI scan predicts clinical response to interferon beta in multiple sclerosis. Eur J Neurol 2009; 16: 1202-09.
3. Rudick RA, Polman CH. Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosis. Lancet Neurol 2009; 8: 545-59.
4. Cox AL, Thompson SA, Jones JL, et al. Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis. Eur J Immunol 2005; 35: 3332-42.
5. Jones JL, Phuah CL, Cox AL, et al. IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J Clin Invest 2009; 119: 2052-61.
6. Thompson SA, Jones JL, Cox AL, et al. B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis. J Clin Immunol 2010; 30: 99-105.
7. Moreau T, Thorpe J, Miller D, et al. Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis. Lancet 1994; 344: 298-301.
8. Coles AJ, Cox A, Le Page E, et al. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol 2006; 253: 98-108.
9. Coles AJ, Wing M, Smith S, et al. Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet 1999; 354: 1691-95.
10. Coles AJ, Wing MG, Molyneux P, et al. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol 1999; 46: 296-304.
11. Fox EJ, Sullivan HC, Gazda SK, et al. A single-arm, open-label study of alemtuzumab in treatment-refractory patients with multiple sclerosis. Eur J Neurol 2012; 19: 307-11.
12. The CAMMS223 Trial Investigators. Alemtuzumab vs. interferon beta 1a in early multiple sclerosis. N Engl J Med 2008; 359: 1786-801.
13. Cohen JA, Coles AJ, Arnold DL, et al, for the CARE-MS I investigators. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 2012; published online Nov 1. http://dx.doi.org/10.1016/S0140-6736(12) 61769-3.
14. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 2005; 58: 840-46.
15. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-52.
16. Cutter GR, Baier ML, Rudick RA, et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 1999; 122: 871-82.
17. Cohen JA, Cutter GR, Fischer JS, et al. Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial. Arch Neurol 2001; 58: 961-67.
18. Hochberg Y, Tamhane AC. Multiple comparison procedures. New York: Wiley, 1987.
19. Lin DY, Wei LJ, Yang I, Ying Z. Semiparametric regression for the mean and rate functions of recurrent event. J R Stat Soc (Series B) 2000; 62: 711-30.
20. Lin DY, Wei LJ. The robust inference for the Cox proportional hazards model. J Am Stat Assoc 1989; 84: 1074-78.
21. Lachin JM. Some large-sample distribution-free estimators and tests for multivariate partially incomplete data from two populations. Stat Med 1992; 11: 1151-70.
22. Wei LJ, Lachin JM. Two-sample asymptotically distribution-free tests for incomplete multivariate observations. J Am Stat Assoc 1984; 79: 653-61.
23. Moreau T, Coles A, Wing M, et al. Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis. Brain 1996; 119: 225-37.
24. Hill-Cawthorne GA, Button T, Tuohy O, et al. Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry 2012; 83: 298-304.
25. Rio J, Nos C, Tintore M, et al. Defining the response to interferonbeta in relapsing-remitting multiple sclerosis patients. Ann Neurol 2006; 59: 344-52.
26. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta 1a for relapsing multiple sclerosis. N Engl J Med 2006; 354: 911-23.
27. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010; 362: 402-15.
28. Panitch H, Goodin DS, Francis G, et al. Randomized, comparative study of interferon beta 1a treatment regimens in MS: the EVIDENCE Trial. Neurology 2002; 59: 1496-506.
29. Limmroth V, Malessa R, Zettl UK, et al. Quality Assessment in Multiple Sclerosis Therapy (QUASIMS): a comparison of interferon beta therapies for relapsing-remitting multiple sclerosis. J Neurol 2007; 254: 67-77.
30. Halpern R, Agarwal S, Borton L, Oneacre K, Lopez-Bresnahan MV. Adherence and persistence among multiple sclerosis patients after one immunomodulatory therapy failure: retrospective claims analysis. Adv Ther 2011; 28: 761-75.
31. Clark RA, Watanabe R, Teague JE, et al. Skin effector memory T cells do not recirculate and provide immune protection in alemtuzumab-treated CTCL patients. Sci Transl Med 2012; 4: 117ra7.
32. Coles AJ, Fox E, Vladic A, et al. Alemtuzumab more effective than interferon beta 1a at 5-year follow-up of CAMMS223 Clinical Trial. Neurology 2012; 78: 1069-78.